Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Lectin, galactoside-binding, soluble, 14 pseudogene (LGALS14 pseudogene) is a non-protein-coding genomic element. While the functional LGALS family members encode galectin proteins involved in cell-cell and cell-matrix interactions, this particular segment of the genome does not produce a functional protein product, lacks demonstrated biological activity, is not associated with known pathologies, and is not a target for therapeutic intervention[2][1]. Note: - If you are searching for a therapeutic target in the galectin family, you may be seeking a functional gene like LGALS3BP (Lectin, galactoside-binding, soluble, 3 binding protein), which is a glycoprotein with roles in cancer progression and immune modulation[3][4]. - ENSG00000268153, however, is unambiguously annotated as a pseudogene and should not be mistaken for an active protein-coding target[2][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lectin, galactoside-binding, soluble, 14 pseudogene (LGALS14 pseudogene).